Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Watson has announced that the US court has granted preliminary injunction preventing Watson and Amphastar from selling Amphastar's Enoxaparin Sodium Injection, as requested by Momenta Pharmaceuticals and Sandoz.
Subscribe to our email newsletter
Enoxaparin, a generic equivalent to Sanofi-aventis’ Lovenox is a low molecular weight heparin used to treat deep vein thrombosis and prophylaxis in unstable angina and non-Q-wave myocardial infarction.
The US FDA has approved Amphastar’s Abbreviated New Drug Application (ANDA) for Enoxaparin Sodium Injection in the 30mg/mL, 40mg/mL, 60mg/mL, 80mg/mL,100mg/mL, 120mg/mL, 150mg/mL and 300mg/mL strengths.
The sole right to distribute Amphastar’s Enoxaparin in the US retail pharmacy channel is held by Watson.